Cognitive Changes for Breast Cancer Survivors
(TRAC Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial aims to understand how thinking and memory change over time in breast cancer survivors compared to individuals without a history of cancer. Participants will complete a one-time online assessment to evaluate memory, attention, and processing speed. Women aged 60-80 who have had stage 0-3 breast cancer, with no current evidence of disease, or women who have never had breast cancer, are suitable for this trial. Participants need access to the internet and a computer to take part. As an unphased study, this trial offers participants the opportunity to contribute to valuable research that may improve understanding of cognitive changes in breast cancer survivors.
Will I have to stop taking my current medications?
If you are taking psychoactive medications (like antidepressants or anxiety meds), your dose must have been stable for at least two months before joining the study. The trial does not specify other medication restrictions, so it's best to discuss your specific situation with the research team.
Why are researchers excited about this trial?
Researchers are excited about this trial because it explores how aging and cancer may affect cognitive functions in breast cancer survivors using a unique approach. Unlike standard neurocognitive assessments, this study utilizes the CogSuite Neurocognitive Battery, which is delivered remotely online, making it accessible and convenient for participants. Additionally, the trial includes DNA analysis through mailed saliva kits to assess Apolipoprotein E (APOE) status, potentially uncovering genetic factors that influence cognitive changes. By combining these innovative methods, the trial aims to gain a deeper understanding of cognitive health in breast cancer survivors, paving the way for more personalized interventions.
Who Is on the Research Team?
James Root, PhD
Principal Investigator
Memorial Sloan Kettering Cancer Center
Are You a Good Fit for This Trial?
Inclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Neurocognitive Assessment
Participants complete a one-time, remote neurocognitive assessment using the CogSuite Neurocognitive Battery and a standard battery of remote neuropsychological measures. DNA is collected via mailed saliva kits to assess Apolipoprotein E (APOE) status.
Follow-up
Participants are monitored for cognitive performance and potential interactions of smoking history with genetic variants on cognition.
What Are the Treatments Tested in This Trial?
Interventions
- TRAC
How Is the Trial Designed?
2
Treatment groups
Experimental Treatment
Enrolled participants will be asked to complete a one-time, remote neurocognitive assessment. The neurocognitive assessment will consist of the CogSuite Neurocognitive Battery, an online, remotely deliverable battery of cognitive experimental measures, and a standard battery of remote neuropsychological measures. DNA will be collected via mailed saliva kits to assess Apolipoprotein E (APOE) status.
Enrolled participants will be asked to complete a one-time, remote neurocognitive assessment. The neurocognitive assessment will consist of the CogSuite Neurocognitive Battery, an online, remotely deliverable battery of cognitive experimental measures, and a standard battery of remote neuropsychological measures. DNA will be collected via mailed saliva kits to assess Apolipoprotein E (APOE) status.
Find a Clinic Near You
Who Is Running the Clinical Trial?
Memorial Sloan Kettering Cancer Center
Lead Sponsor
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.